Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 800

Sort by

Sort Order Select

Journal Articles

Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect

Kaushik Das, Shiva Keshava, Shabbir A. Ansari, Vijay Kondreddy, Charles T. Esmon, John H. Griffin, Usha R. Pendurthi, L. Vijaya Mohan Rao

Blood (2021) 137 (24): 3428–3442.

https://doi.org/10.1182/blood.2020008417

Published: 2021

Includes: Supplemental data

Journal Articles

von Willebrand disease: what does the future hold?

Cécile V. Denis, Sophie Susen, Peter J. Lenting

Blood (2021) 137 (17): 2299–2306.

https://doi.org/10.1182/blood.2020008501

Published: 2021

Journal Articles

In hemophilia, it just keeps getting better

Aric Parnes

Blood (2021) 137 (16): 2135–2136.

https://doi.org/10.1182/blood.2020010238

Published: 2021

Journal Articles

Prophylaxis in hemophilia: how much is enough?

Christine L. Kempton

Blood (2021) 137 (13): 1709–1711.

https://doi.org/10.1182/blood.2020009603

Published: 2021

Journal Articles

EPCR deficiency or function-blocking antibody protects against joint bleeding–induced pathology in hemophilia mice

Jhansi Magisetty, Usha R. Pendurthi, Charles T. Esmon, L. Vijaya Mohan Rao

Blood (2020) 135 (25): 2211–2223.

https://doi.org/10.1182/blood.2019003824

Published: 2020

Includes: Supplemental data

Journal Articles

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Pratima Chowdary, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupancic-Salek, Johannes Oldenburg

Blood (2019) 134 (22): 1973–1982.

https://doi.org/10.1182/blood.2019001542

Published: 2019

Includes: Multimedia, Supplemental data

Journal Articles

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Michael F. Guerrera, MD, Gita Massey, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 2396.

https://doi.org/10.1182/blood-2019-126944

Published: 2019

Journal Articles

Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy

Felipe Querol, MD PhD, Sofía Pérez-Alenda, PhD, Juan Eduardo Megias, Juan José Carrasco, MSc, Marta Aguilar, PhD, Saturnino Haya, MD, Ana R Cid, Santiago Bonanad Boix, MD

Blood (2019) 134 (Supplement_1): 2455.

https://doi.org/10.1182/blood-2019-125651

Published: 2019

Journal Articles

Associated Co-Morbidities, Healthcare Utilization, and Mortality in Hospitalized Children and Adults with Hemophilia in the United States: Updated Nationally Representative Estimates and a Comparative Analysis

Ashwin Gupta, Abdul Hannan, MD, Ruby Maini, MD, Stephanie Bitner, Pharm D, Schuyler Stone, MD, Manjari Regmi, MD, Aaron Tobian, MD PhD, Cassandra D Josephson, MD, Lakshmanan Krishnamurti, MD, Clifford M. Takemoto, MD, Ruchika Goel, MD MPH

Blood (2019) 134 (Supplement_1): 4711.

https://doi.org/10.1182/blood-2019-123161

Published: 2019

Journal Articles

Pharmacoeconomic Analysis of Ideal Vs. Actual Body Weight-Based Treatment for Adult Persons with Hemophilia Α

Ming Y. Lim, MBBChir,MA, Jeffrey A. Gilreath, PharmD, Paul F. Bray, MD, George M. Rodgers, MD PhD

Blood (2019) 134 (Supplement_1): 4684.

https://doi.org/10.1182/blood-2019-121679

Published: 2019

Journal Articles

Electronic Health Record Tools to Promote Transition Readiness and Knowledge for Adolescents and Young Adults with Hemophilia

Jacob Parker, Clinical Informaticist, Katharine Farrow, RN, BSN, Rosalie Brooks, RN, Danielle Leonard, BS, Fernanda Cortez, Courtney D. Thornburg, MD

Blood (2019) 134 (Supplement_1): 4685.

https://doi.org/10.1182/blood-2019-124561

Published: 2019

Journal Articles

Quantitative Measurements of Hemophilic Joint Tissues By Point-of-Care Musculoskeletal Ultrasound Are Associated with Clinical and Functional Joint Outcome Parameters

Akram Mesleh Shayeb, MD, Richard Barnes, PhD MPH, Cris Hanacek, BS, Andres Flores, MS, ATC, CES, Rebecca Kruse-Jarres, MDMPH, Bruno Steiner, PT, DPT, LMT, RMSK, Doris Quon, MD PhD, Cindy Bailey, DPT, OCS, SCS, ATC, Annette von Drygalski, MD PharmD

Blood (2019) 134 (Supplement_1): 905.

https://doi.org/10.1182/blood-2019-129690

Published: 2019

Journal Articles

The Use of Chromogenic Factor VIII Assay Changes Treatment Approach in a Portion of Mild Hemophilia A Patients with Factor VIII Assay Discrepancy

Muntadhar Al Moosawi, MD, Karen L. Dallas, MD FRCPC, Steven Wong, Shannon Jackson, MD FRCPC

Blood (2019) 134 (Supplement_1): 906.

https://doi.org/10.1182/blood-2019-123799

Published: 2019

Journal Articles

Validation of Instrument to Assess Hemophilia-Related Distress

Christine L. Kempton, MD MSc, Vaughn Barry, PhD MPH, Tyler W. Buckner, MD MSc, Janet Figueroa, MPH, Shanna Mattis, MPH, Mary Ellen Lynch, PhD, Mary E Stout, MD, Stephanie Whitten, Scott Gillespie, Courtney McCracken, PhD

Blood (2019) 134 (Supplement_1): 936.

https://doi.org/10.1182/blood-2019-122544

Published: 2019

Journal Articles

Higher Incidence of Neutralizing Anti-FVIII Antibodies (Inhibitors) in Black and Hispanic American Hemophilia A Patients Enrolled in the My Life, Our Future Programme

Kathleen P. Pratt, PhD

Blood (2019) 134 (Supplement_1): 901.

https://doi.org/10.1182/blood-2019-127412

Published: 2019

Journal Articles

Obtaining a Von Willebrand Evaluation at Time of Acute Heavy Menstrual Bleeding Presentation Leads to Overestimation of Von Willebrand Levels

Megan C. Brown, MD, Michael H. White, MD, Robert F. Sidonio, Jr., MD MSc

Blood (2019) 134 (Supplement_1): 627.

https://doi.org/10.1182/blood-2019-127258

Published: 2019

Journal Articles

Long-Term AAV-Mediated Factor VIII Expression in Nine Hemophilia A Dogs: A 10 Year Follow-up Analysis on Durability, Safety and Vector Integration

Giang N. Nguyen, BS, John K. Everett, PhD, Hayley Raymond, BA, Samita Kafle, BS, Elizabeth P. Merricks, PhD, Haig H. Kazazian, MD, Timothy C. Nichols, MD, Frederic D. Bushman, PhD, Denise E. Sabatino, PhD

Blood (2019) 134 (Supplement_1): 611.

https://doi.org/10.1182/blood-2019-126007

Published: 2019

Journal Articles

The Tissue Factor Pathway Inhibitor Gamma Knockout Mouse Is a Better Model Than the Wild Type Mouse for Studying Tissue Factor-Related Human Diseases

Thomas J. Girard, Nina M. Lasky, Dhanalakshmi S. Anbukumar, George J. Broze, Jr.

Blood (2019) 134 (Supplement_1): 484.

https://doi.org/10.1182/blood-2019-130360

Published: 2019

Journal Articles

Double-Blind, Randomized Study of Canakinumab Treatment in Pediatric and Young Adult Patients with Sickle Cell Anemia

Blood (2019) 134 (Supplement_1): 615.

https://doi.org/10.1182/blood-2019-123355

Published: 2019

Journal Articles

Assessing the Safety of Various VWF Regimens in Patients with Clinically Severe VWD: A Natural History Study

Robert F. Sidonio, Jr., MD MSc, Angela C. Weyand, MD, Dunlei Cheng, PhD, Crystal Watson

Blood (2019) 134 (Supplement_1): 1132.

https://doi.org/10.1182/blood-2019-128318

Published: 2019

NARROW

Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect

von Willebrand disease: what does the future hold?

In hemophilia, it just keeps getting better

Prophylaxis in hemophilia: how much is enough?

EPCR deficiency or function-blocking antibody protects against joint bleeding–induced pathology in hemophilia mice

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy

Associated Co-Morbidities, Healthcare Utilization, and Mortality in Hospitalized Children and Adults with Hemophilia in the United States: Updated Nationally Representative Estimates and a Comparative Analysis

Pharmacoeconomic Analysis of Ideal Vs. Actual Body Weight-Based Treatment for Adult Persons with Hemophilia Α

Electronic Health Record Tools to Promote Transition Readiness and Knowledge for Adolescents and Young Adults with Hemophilia

Quantitative Measurements of Hemophilic Joint Tissues By Point-of-Care Musculoskeletal Ultrasound Are Associated with Clinical and Functional Joint Outcome Parameters

The Use of Chromogenic Factor VIII Assay Changes Treatment Approach in a Portion of Mild Hemophilia A Patients with Factor VIII Assay Discrepancy

Validation of Instrument to Assess Hemophilia-Related Distress

Higher Incidence of Neutralizing Anti-FVIII Antibodies (Inhibitors) in Black and Hispanic American Hemophilia A Patients Enrolled in the My Life, Our Future Programme

Obtaining a Von Willebrand Evaluation at Time of Acute Heavy Menstrual Bleeding Presentation Leads to Overestimation of Von Willebrand Levels

Long-Term AAV-Mediated Factor VIII Expression in Nine Hemophilia A Dogs: A 10 Year Follow-up Analysis on Durability, Safety and Vector Integration

The Tissue Factor Pathway Inhibitor Gamma Knockout Mouse Is a Better Model Than the Wild Type Mouse for Studying Tissue Factor-Related Human Diseases

Double-Blind, Randomized Study of Canakinumab Treatment in Pediatric and Young Adult Patients with Sickle Cell Anemia

Assessing the Safety of Various VWF Regimens in Patients with Clinically Severe VWD: A Natural History Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only